PCJ Stock Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Abeona Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.08 |
| 52 Week High | US$8.06 |
| 52 Week Low | US$2.64 |
| Beta | 1.48 |
| 1 Month Change | -53.68% |
| 3 Month Change | -27.87% |
| 1 Year Change | 11.19% |
| 3 Year Change | -90.93% |
| 5 Year Change | -98.20% |
| Change since IPO | -97.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| PCJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -55.0% | 0.7% | 2.0% |
| 1Y | 11.2% | -24.4% | 2.0% |
Return vs Industry: PCJ exceeded the German Biotechs industry which returned -22.8% over the past year.
Return vs Market: PCJ exceeded the German Market which returned 1.3% over the past year.
Price Volatility
| PCJ volatility | |
|---|---|
| PCJ Average Weekly Movement | 20.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: PCJ's share price has been volatile over the past 3 months.
Volatility Over Time: PCJ's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 84 | Vish Seshadri | www.abeonatherapeutics.com |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
Abeona Therapeutics Inc. Fundamentals Summary
| PCJ fundamental statistics | |
|---|---|
| Market cap | €81.57m |
| Earnings (TTM) | -€50.65m |
| Revenue (TTM) | €3.27m |
25.5x
P/S Ratio-1.6x
P/E RatioIs PCJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCJ income statement (TTM) | |
|---|---|
| Revenue | US$3.50m |
| Cost of Revenue | US$2.69m |
| Gross Profit | US$810.00k |
| Other Expenses | US$55.00m |
| Earnings | -US$54.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | 23.14% |
| Net Profit Margin | -1,548.23% |
| Debt/Equity Ratio | 0% |
How did PCJ perform over the long term?
See historical performance and comparison